Interventional Study for Detection of Prognosis of Blood Based Biomarkers in Intracerebral Hemorrhage
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Intracerebral Hemorrhage. Basic parameters: 20 years — 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Predictive Value of Blood-based Biomarkers on the Functional Outcome in Young Adult Patients with Spontaneous Intracerebral Hemorrhage
Overview
Explore blood based biomarkers in patients with intracerebral haemorrhage \[cbc. Pt. LDH.CRP. Cholesterol. Na. K.. Mg. Urea Ca. Uric acid\]
Detailed description
Spontaneous intracerebral hemorrhage (ICH) is a common subtype of stroke and accounts for nearly 10% to 30% of all strokes \[1\]. ICH posed a significant health burden in China in 2019, contributing to 25 million disability-adjusted life years (DALYs). It is associated with an early mortality rate of approximately 30-40% and has shown no reduction in prevalence in recent decades \[2\]. The higher incidence and mortality of ICH in middle-income and low-income countries may be attributed to limited public awareness regarding preventive measures, as well as challenges in accessing healthcare services \[3\]. So far, few treatment possibilities have yielded conclusive benefits. However, numerous predictors of poor outcomes after ICH have been suggested, including hematoma volume, hematoma expansion, perihematomal edema (PHE), and the presence and quantity of intraventricular hemorrhage growth \[4,5,6,7\]. Similarly, researchers continue to search for various blood-based biomarkers to guide management and predict outcomes after acute ICH \[8,9,10,11,12\]. A growing number of studies have shown that many novel biomarkers, such as C-reactive protein (CRP), S100A12, and interleukin-6, are associated with adverse outcomes in patients with ICH \[8,9,10\]. Thus, the application of blood-based biomarkers may improve risk stratification and aid clinical decisions in patients with ICH.
Therefore, in this review, we assessed the data available in the literature regarding the diagnostic and prognostic value of circulating blood biomarkers in patients with ICH. For each biomarker, we depicted the detailed characteristics in order to shed light on potential future clinical applications Intracerebral hemorrhage (ICH) is the second most common subtype of stroke and a critical disease usually leading to severe disability or death. ICH is more common in advanced age, male sex, and low- and middle-income countries. The case fatality rate of ICH is high, and only 12% to 39% of survivors can achieve long-term functional independence. Risk factors of ICH are hypertension, current smoking, excessive alcohol consumption, hypocholesterolemia, and drugs. Clinical presentation varies according to the size and location of hematoma, and intraventricular extension of hemorrhage.
Primary outcome measures
- : Predictive value of blood-based biomarkers on the functional outcome in young adult patients with spontaneous intracerebral hemorrhage. [Time frame: 2 years]
- : Predictive value of blood-based biomarkers on the functional outcome in young adult patients with spontaneous intracerebral hemorrhage. [Time frame: 2 years]
Secondary outcome measures (1)
- : Predictive value of blood-based biomarkers on the functional outcome in young adult patients with spontaneous intracerebral hemorrhage. [Time frame: 2 years]
Eligibility criteria
- Inclusion criteria:
- both sex
- Age between 25 to 40 years old.
- symptoms suggestive of intracerebral hemorrhage
Exclusion criteria
<!-- -->
- Age group below 25 years and above 40 years
- traumatic cerebral haemorrhage
- extradural,subdural,subarachnoid hemorrhage
- Hemorrhagic infarction
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06745037 · Intracerebral hemorrhage